Gelteq Limited announced the appointment of Dr. Paul Wynne as its Chief Scientific Officer (CSO). Dr. Wynne's distinguished record and expertise are expected to be instrumental in advancing Gelteq's innovative ingestible gel technology.
Dr. Wynne brings extensive experience in formulation science and drug delivery systems to the company. His leadership will be key in propelling Gelteq's research and development initiatives.
This appointment reinforces Gelteq's commitment to scientific excellence and innovation in its core verticals. It is anticipated to strengthen the company's ability to develop and commercialize its unique gel-based delivery solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.